MA34301B1 - Nouveaux procedes - Google Patents

Nouveaux procedes

Info

Publication number
MA34301B1
MA34301B1 MA35441A MA35441A MA34301B1 MA 34301 B1 MA34301 B1 MA 34301B1 MA 35441 A MA35441 A MA 35441A MA 35441 A MA35441 A MA 35441A MA 34301 B1 MA34301 B1 MA 34301B1
Authority
MA
Morocco
Prior art keywords
new processes
formula
processes
atherosclerosis
preparing
Prior art date
Application number
MA35441A
Other languages
English (en)
French (fr)
Inventor
Kevin Stuart Cardwell
Claire Frances Crawford
Suzanne Helen Davies
Charles Edward Wade
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44992024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34301(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA34301B1 publication Critical patent/MA34301B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups
    • C07C227/06—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups
    • C07C227/06—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
    • C07C227/08—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid by reaction of ammonia or amines with acids containing functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MA35441A 2010-05-17 2011-05-17 Nouveaux procedes MA34301B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34522410P 2010-05-17 2010-05-17
PCT/US2011/036821 WO2011146494A1 (en) 2010-05-17 2011-05-17 Novel processes

Publications (1)

Publication Number Publication Date
MA34301B1 true MA34301B1 (fr) 2013-06-01

Family

ID=44992024

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35441A MA34301B1 (fr) 2010-05-17 2011-05-17 Nouveaux procedes

Country Status (25)

Country Link
US (2) US9447052B2 (enExample)
EP (1) EP2571857B1 (enExample)
JP (1) JP6027529B2 (enExample)
KR (1) KR20130089157A (enExample)
CN (2) CN105837520A (enExample)
AR (1) AR081399A1 (enExample)
AU (1) AU2011256270B2 (enExample)
BR (1) BR112012030532A2 (enExample)
CA (1) CA2799520C (enExample)
CL (1) CL2012003206A1 (enExample)
CO (1) CO6630197A2 (enExample)
CR (1) CR20120630A (enExample)
DO (1) DOP2012000289A (enExample)
EA (1) EA026569B1 (enExample)
IL (1) IL223068A0 (enExample)
MA (1) MA34301B1 (enExample)
MX (1) MX2012013387A (enExample)
NZ (1) NZ603672A (enExample)
PE (1) PE20130318A1 (enExample)
PH (1) PH12012502247A1 (enExample)
SG (1) SG185559A1 (enExample)
TW (1) TW201209043A (enExample)
UY (1) UY33388A (enExample)
WO (1) WO2011146494A1 (enExample)
ZA (1) ZA201208631B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201209043A (en) * 2010-05-17 2012-03-01 Glaxo Group Ltd Novel processes
WO2015087239A1 (en) 2013-12-11 2015-06-18 Ranbaxy Laboratories Limited Processes for the preparation of darapladib and its intermediates
WO2015092687A2 (en) 2013-12-17 2015-06-25 Ranbaxy Laboratories Limited Process for the purification of darapladib
ES2907130T3 (es) 2017-09-26 2022-04-22 Inst Nat Sante Rech Med Darapladib radiomarcado, análogos del mismo y su uso como compuestos para la obtención de imágenes
US10866963B2 (en) * 2017-12-28 2020-12-15 Dropbox, Inc. File system authentication
CN118221687B (zh) 2023-07-17 2024-12-31 上海枢境生物科技有限公司 双环[5,6]咪唑嘧啶酮类衍生物、其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1143516B (de) * 1961-04-27 1963-02-14 Bayer Ag Verfahren zur Herstellung von Peptiden
US4277465A (en) 1978-08-26 1981-07-07 Kyoto Yakuhin Kogyo Kabushiki Kaisha Adjuvant for promoting absorption of therapeutically active substances through the digestive tract
US4235776A (en) * 1979-03-15 1980-11-25 Eli Lilly And Company Tetrahydro-2H-benzo[c]pyrroles
DE2941597A1 (de) * 1979-10-13 1981-04-23 Basf Ag, 6700 Ludwigshafen Piperidinderivate von 4,5-dialkyl-3-hydroxy-pyrrol-2-carbonsaeureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
US4619941A (en) * 1984-11-19 1986-10-28 American Cyanamid Company N-[(1H-imidazol-1-yl)alkyl]-1H-indolecarboxamides useful as thromboxane synthetase inhibitors and antihypertensive agents
WO1999024420A1 (en) 1997-11-06 1999-05-20 Smithkline Beecham Plc Pyrimidinone compounds and pharmaceutical compositions containing them
US6750228B1 (en) * 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
WO2000028328A1 (en) 1998-11-05 2000-05-18 Biocryst Pharmaceuticals, Inc. New cyclopentane and cyclopentene compounds and use for detecting influenza virus
DE60042286D1 (de) * 1999-05-01 2009-07-09 Smithkline Beecham Plc Pyrimidinon Verbindungen
DE60139429D1 (de) * 2000-02-16 2009-09-10 Smithkline Beecham Plc Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren
GB0119795D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel process
TW201209043A (en) * 2010-05-17 2012-03-01 Glaxo Group Ltd Novel processes

Also Published As

Publication number Publication date
EP2571857A4 (en) 2013-11-20
NZ603672A (en) 2015-01-30
EA026569B1 (ru) 2017-04-28
PE20130318A1 (es) 2013-04-11
IL223068A0 (en) 2013-02-03
CN105837520A (zh) 2016-08-10
CN103003249B (zh) 2016-04-27
SG185559A1 (en) 2012-12-28
MX2012013387A (es) 2012-12-10
TW201209043A (en) 2012-03-01
US20130060028A1 (en) 2013-03-07
CL2012003206A1 (es) 2013-01-25
US9447052B2 (en) 2016-09-20
KR20130089157A (ko) 2013-08-09
BR112012030532A2 (pt) 2015-09-29
EA201291235A1 (ru) 2013-04-30
AR081399A1 (es) 2012-08-29
WO2011146494A1 (en) 2011-11-24
JP6027529B2 (ja) 2016-11-16
EP2571857B1 (en) 2017-08-23
US20160347720A1 (en) 2016-12-01
AU2011256270A1 (en) 2012-12-20
CO6630197A2 (es) 2013-03-01
CA2799520A1 (en) 2011-11-24
JP2013530948A (ja) 2013-08-01
UY33388A (es) 2011-12-01
CN103003249A (zh) 2013-03-27
EP2571857A1 (en) 2013-03-27
US9725420B2 (en) 2017-08-08
PH12012502247A1 (en) 2013-02-04
CR20120630A (es) 2013-02-15
ZA201208631B (en) 2013-09-25
AU2011256270B2 (en) 2015-11-26
CA2799520C (en) 2016-09-13
DOP2012000289A (es) 2013-04-15

Similar Documents

Publication Publication Date Title
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
MX2009013591A (es) Proceso para la preparacion de pirazoles.
IL198226A0 (en) 2-[l-phenyl-5-hydroxy-4alpha-methyl
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA34641B1 (fr) Anticorps anti-il-23
MA32551B1 (fr) Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires
MX2009013830A (es) Compuestos antivirales.
UA98494C2 (uk) Противірусні сполуки
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
CY1113131T1 (el) Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
EA201200018A1 (ru) Триазольные соединения, несущие серосодержащий заместитель
MX340572B (es) Proceso para la fabricacion de compuestos farmaceuticamente activos.
MA33492B1 (fr) Inhibiteurs de bace
MA31834B1 (fr) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires
MA35086B1 (fr) Compose de triazolopyridine
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
IN2014MN01521A (enExample)
MX2012002641A (es) Inhibidores de cinasa janus (jak).
CY1112829T1 (el) Νεα μεθοδος συνθεσης για την αγομελατινη
MX2020009790A (es) Proceso para fabricar compuestos de quinolona.
MA31526B1 (fr) Nouveaux herbicides
UA103329C2 (ru) Соли соединений-ингибиторов вич
PH12012502247A1 (en) Novel processes
MA20150280A2 (fr) Dérivés d'aryléthynyle
TW200710084A (en) Process for the synthesis of organic compounds